BTIG Research Raises Teva Pharmaceutical Industries (TEVA) Price Target to $20.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price increased by equities research analysts at BTIG Research to $20.00 in a report released on Friday. BTIG Research’s price objective would suggest a potential upside of 15.61% from the stock’s current price.

Other analysts also recently issued reports about the stock. BidaskClub raised shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 13th. Cantor Fitzgerald set a $10.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday. Piper Jaffray Companies set a $16.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday. Finally, Wells Fargo & Company reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday. Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $19.49.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at $17.30 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $38.31. The stock has a market cap of $15,951.20, a price-to-earnings ratio of 3.63 and a beta of 0.55.

Large investors have recently modified their holdings of the stock. San Francisco Sentry Investment Group CA bought a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $106,000. Bronfman E.L. Rothschild L.P. boosted its holdings in Teva Pharmaceutical Industries by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after acquiring an additional 94 shares during the period. Shelter Mutual Insurance Co bought a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $133,000. Fayez Sarofim & Co. bought a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $204,000. Finally, Community Bank & Trust Waco Texas bought a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $210,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BTIG Research Raises Teva Pharmaceutical Industries (TEVA) Price Target to $20.00” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/15/btig-research-raises-teva-pharmaceutical-industries-teva-price-target-to-20-00.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Leave a Reply